OBJECTIVE: To investigate whether transient-evoked and distortion-product (DP) @entity392 ( @entity392 ) are more sensitive than pure-tone audiometry (PTA) in revealing @entity801 -induced @entity2167 in @entity1 with @entity1577 ( @entity1577 ). DESIGN: Prospective case-control study. SETTING: Tertiary referral audiologic center in conjunction with an academic pediatric @entity1577 unit. @entity1 : The study group consisted of a consecutive sample of 12 audiologically normal @entity1 with @entity1577 and a history of @entity801 exposure ( @entity1577 - @entity801 group). The control groups consisted of 8 age-matched @entity1 with @entity1577 and 11 age-matched healthy volunteers. No member of the control groups had a history of @entity4028 exposure. INTERVENTION: Members of the @entity1577 - @entity801 study group received 4 mg/kg of @entity801 per day for a mean of 14.2 days (range, 11-29 days). OUTCOME MEASURES: The PTA thresholds (250-8000 Hz) were the criterion standard. @entity392 ' reproducibility at 5 frequency bands (800, 1600, 2400, 3200, and 4000 Hz) and total emission level were measured, as were DP-audiogram (DP-gram) amplitude (1001-6299 Hz), input-output function dynamic range, and detection thresholds at 4004, 6006, and 7996 Hz. Baseline measurements were compared between groups examining the effect of @entity1577 and previous @entity801 exposure (2-way analysis of variance). For the @entity1577 - @entity801 group, baseline measurements were compared with those at the end of the last @entity801 treatment (paired t test). RESULTS: The PTA findings were normal for all groups at baseline and remained normal in the @entity1577 - @entity801 group after treatment. The @entity1577 - @entity801 group had significantly lower transient-evoked @entity392 total emission level, DP-gram amplitude at 5042 Hz, and input-output dynamic ranges with higher detection thresholds in all frequencies compared with both control groups, which was attributed completely to previous @entity801 exposure (P<.05). After treatment, further decreases in total emission levels, DP-gram amplitudes (>3000 Hz), and dynamic ranges were noted, with increased detection thresholds (P<.05). CONCLUSIONS: Otoacoustic emissions measurement (especially of DP @entity392 ) proved more sensitive than @entity865 in revealing @entity18129 after @entity801 exposure. They should be used for monitoring @entity1 receiving ototoxic factors such as @entity581 .

Otoacoustic emissions for monitoring @entity4028 -induced XXXX in @entity1 with @entity1577 .

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'PARTICIPANTS'] @entity801 :: ('MESH:D005839', 'Chemical') :: ['gentamicin'] @entity18129 :: ('MESH:D015834', 'Disease') :: ['minor cochlear dysfunction'] @entity2167 :: ('MESH:D006311', 'Disease') :: ['ototoxicity'] @entity4028 :: ('CHEBI:47779', 'Chemical') :: ['aminoglycoside'] @entity392 :: ('MESH:D014012', 'Disease') :: ['otoacoustic emissions', 'Transient-evoked OAEs', 'OAEs'] @entity865 :: ('CHEBI:61432', 'Chemical') :: ['PTA'] @entity581 :: ('MESH:D000617', 'Chemical') :: ['aminoglycosides'] @entity1577 :: ('MESH:D003550', 'Disease') :: ['cystic fibrosis', 'CF']
@entity2167 :: (MESH:D006311,Disease) :: ['ototoxicity']
